2022 World Conference on Lung Cancer (ePosters)-EP05.01-001. Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity

EP05.01-001. Hispanic Patients with Unresectable Stage III NSCLC under PACIFIC Protocol: Evidence of Interior Outcomes and Health Inequity

Back to course

Pdf Summary

A retrospective study comparing outcomes in Hispanic and non-Hispanic White (NHW) patients with locally advanced (LA) stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiation (cCRT) followed by durvalumab found inferior outcomes and lack of health equity in Hispanic patients. The study included 80 Hispanic and 45 NHW patients, and the main outcomes analyzed were overall survival (OS), progression-free survival (PFS), and safety. The overall response rate (ORR) was 57.6%, and OS was 26.3 months. PFS was 20.5 months. When comparing outcomes by ethnicity, the NHW group had a significantly higher OS compared to Hispanics (27.7 months vs. 20.0 months). The unadjusted 12-month and 24-month OS rates were also higher in NHW patients compared to Hispanics. The study found that Hispanics had a reduced survival compared to NHW and the PACIFIC trial population, with an efficacy-effectiveness (EE) factor of 0.58. The hazard ratio (HR) for OS was higher in Hispanics compared to NHW. There was no significant difference in the proportion or severity of pneumonitis between Hispanics and NHW patients. The study suggests that NHW patients had better survival outcomes than Hispanics, indicating a lack of health equity in the treatment of stage III NSCLC. These findings highlight the need for further research and interventions to address health disparities and improve outcomes for Hispanic patients with NSCLC.

Asset Subtitle

Andres F Cardona

Meta Tag

Speaker Andres F Cardona

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

retrospective study

Hispanic

non-Hispanic White

locally advanced

stage III

non-small cell lung cancer

concurrent chemoradiation

durvalumab

overall survival

progression-free survival